<DOC>
	<DOCNO>NCT02328105</DOCNO>
	<brief_summary>ABRAXANE , base result prior study , promise drug squamous cell carcinoma lung . This study help explore combination ABRAXANE carboplatin thoroughly subgroup patient best response prior study well determine whether biomarkers predict response .</brief_summary>
	<brief_title>LCI-LUN-ABR-001 : Carbo With Nab-Paclitaxel Patients With Advanced NSCL Cancer</brief_title>
	<detailed_description>This single arm phase II study subject receive first line therapy metastatic squamous cell lung cancer . Following informed consent eligibility check , subject receive therapy carboplatin ABRAXANE outpatient basis . A total 50 subject enrolled enrollment period 24 month . Interim analyse conduct enrollment subject 15 , subject 30 , subject 45 . Tissue biomarkers analyze baseline ; blood biomarkers analyze baseline , pre-dose cycle 3 5 , within 30 day last dose study treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm stage IV nonsmall cell lung cancer predominantly squamous histology No prior systemic treatment metastatic disease . Patients receive prior adjuvant chemotherapy earlystage lung cancer eligible least 12 month elapse date final chemotherapy administration date consent Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) &gt; 20 mm conventional technique &gt; 10 mm CT scan , MRI , caliper clinical exam Biopsy accessible disease Patients previous radiotherapy definitive therapy locally advance nonsmall cell lung cancer eligible , long recurrence outside original radiation therapy port . Definitive radiation therapy must complete &gt; 4 week prior date informed consent sign Age &gt; 18 year ECOG performance status less equal 1 If patient brain metastasis , disease must stable ( treated and/or asymptomatic ) least 4 week prior first dose study treatment Bilirubin &lt; 1.5 mg/dL Adequate liver function : AST ALT &lt; = 2.5x upper limit normal , alkaline phosphatase &lt; = 2.5x upper limit normal , unless bone metastasis present ( &lt; 5x upper limit normal ) absence liver metastasis Adequate bone marrow function : Platelets &gt; 100,000 cells/mm3 , Hemoglobin &gt; 9.0g/dL ANC &gt; 1,500 cells/mm3 Adequate renal function creatinine &lt; 1.5 mg/dL recommend Females childbearing potential sexually active male must use effective contraception method treatment six month complete treatment Negative serum urine BhCG pregnancy test screening patient childbearing potential Patients must &lt; Grade 2 preexist peripheral neuropathy ( per CTCAE version 4.0 ) Ability understand willingness sign write informed consent document Exclusion Criteria Received prior systemic therapy metastatic disease Received limit field radiation palliation &lt; = 2 week prior start study treatment and/or &gt; = 30 % bone marrow irradiate Receiving investigational agent Known hypersensitivity either carboplatin ABRAXANE Uncontrolled current illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breast feed Other active malignancy Neuropathy great equal grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>